Rethinking governance of synthetic cells
Frontiers in Bioengineering and Biotechnology · 09.07.2026 · 14
DOI: 10.3389/fbioe.2026.1872353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 09.07.2026. Verfasst von David R Gillum und 3 weiteren Autor:innen. Beteiligte Einrichtung: Compliance and Research Administration, University of Nevada, Reno, Reno, NV, United States. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Synthetic cells represent a class of engineered biological systems that span a continuum from non-replicating biochemical assemblies to genome-containing entities, exposing limitations in conventional approaches to biotechnology governance. These systems are enabled by advances in synthetic nucleic acid technologies, which provide the basis for their design, function, and programmability and expand the accessible design space of engineered biological systems. Building on a recent National Academies report, this perspective argues that continued advances in nucleic acid synthesis and design are a key driver of emerging biosafety and biosecurity challenges, particularly by challenging assumptions embedded in sequence- and organism-based approaches to oversight. We treat synthetic cells as a boundary case that highlights limitations in nucleic-acid-enabled biotechnology governance. Drawing on the report’s property-based framework, we examine how governance misalignment arises in practice through the interaction of categorical triggers, institutional boundaries, and the timing of oversight across the research and development lifecycle. We further highlight limitations in how current risk assessment approaches are applied and provide structured questions that more explicitly support the evaluation of benefits alongside risks to improve consistency in function- and context-based assessment across institutional and policy settings. Together, these observations underscore the need to align governance approaches with system properties, intended use, and deployment context as engineering biology continues to expand beyond conventional biological categories.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Compliance and Research Administration, University of Nevada, Reno, Reno, NV, United States.
- RTX BBN Technologies, Cambridge, MA, United States.
- Engineering Biology Research Consortium, Emeryville, CA, United States.
- National Academies of Sciences, Engineering, and Medicine, Washington, DC, United States.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Gillum, D. R., Carr, P. A., Hook-Barnard, I., & Tucholski, T. (2026). Rethinking governance of synthetic cells. Frontiers in Bioengineering and Biotechnology, 14. https://doi.org/10.3389/fbioe.2026.1872353
Vancouver
Gillum DR, Carr PA, Hook-Barnard I, Tucholski T. Rethinking governance of synthetic cells. Frontiers in Bioengineering and Biotechnology. 2026;14. doi:10.3389/fbioe.2026.1872353
BibTeX
@article{Gillum2026,
author = {Gillum, David R and Carr, Peter A and Hook-Barnard, India and Tucholski, Trisha},
title = {Rethinking governance of synthetic cells},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2026},
volume = {14},
doi = {10.3389/fbioe.2026.1872353}
}
EUVIMED